Please login to the form below
Tredaptive
This page shows the latest Tredaptive news and features for those working in and with pharma, biotech and healthcare.
FDA rejects Merck muscle relaxant drug once again
this year after disappointments such as the failure of cholesterol drug Tredaptive (extended-release niacin/laropiprant).
Latest news
-
Merck & Co inches closer to US green light for insomnia drug
The company suffered another R&D setback recently when it dropped development of another phase III project – cardiovascular treatment Tredaptive ER (laropiprant and niacin) – after disappointing results in the HPS-2
-
Merck cuts outlook as Q1 sales fall
including the failure of cholesterol drug Tredaptive (extended-release niacin/laropiprant).
-
Former Amgen R&D head Perlmutter to lead research at Merck & Co
The company recently dropped cholesterol drug Tredaptive (extended-release niacin/laropiprant) after disappointing results in a trial, which showed it was no more effective than statins but increased the risk of
-
MHRA plays catch up with pharma on Twitter
But the use of new, separate accounts for medicines and medical devices seems logical, given the differences in audience for a recall of Merck Sharp &Dohme's Tredaptive versus that for
-
EMA recommends suspension of Merck's Tredaptive
The EMA's confirmation now seals Tredaptive's fate, and the regulator recommended patients taking the medicine should make a non-urgent appointment with their doctor to discuss treatment options. ... Outside Europe, Merck has already said it does not
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Closing the treatment gap
This included a global release available at the press event and distribution over the wires, a glossy media guide to cardiovascular disease, fact sheets on heart disease, Merck’s drug Tredaptive
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU outlines measures to mitigate antibiotic shortage across Europe
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Merging global and local pharmacovigilance operations into a successful integrated approach
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
